Active substanceCefoperazoneCefoperazone
Similar drugsTo uncover
  • Medoceph
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movoperiz®
    powdersolution w / m in / in 
  • Opera
    powder w / m in / in 
  • Zeperon J
    powdersolution w / m in / in 
  • Cefobide
    powdersolution w / m in / in 
    Pfizer Inc.     USA
  • Cefoperabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Cefoperazone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Cefoperazone-Agio
    powdersolution w / m in / in 
  • Cefoperazone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Cefoperus®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Cephar
    powdersolution w / m in / in 
  • Dosage form: & nbspPowder for the preparation of solution for intravenous and intramuscular injection.
    Composition:
    One bottle contains:

    active substance: sodium cefoperazone (in terms of cefoperazone) - 0.5 g, 1 g, 2 g
    Description:
    White or white with a yellowish tint powder.

    Pharmacotherapeutic group:Antibiotic-cephalosporin.
    ATX: & nbsp

    J.01.D.D.12   Cefoperazone

    Pharmacodynamics:
    Cefoperus® is a semisynthetic cephalosporin antibiotic of the third generation of a broad spectrum of antibacterial action.
    Has a bactericidal effect due to inhibition of bacterial cell wall synthesis. It is active in vitro against a large number of clinically relevant microorganisms. Resistant to the action of many beta-lactamases.
    By cefoperazone sensitive following microorganisms: Gram positive - Staphylococcus aureus (strains producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic streptococcus Group A), Streptococcus agalactiae (beta-hemolytic Streptococcus group B), Enterococcus (Streptococcus faecalis, S. faecium and S. durans);
    Gram-negative: Escherichia coli, Klebsiella species (including K. pneumoniae, Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii; Providencia stuartii, Providencia rettgeri, Serratia marcescens, Pseudomonas aeruginosa, Pseudomonas spp., Some strains of Acinetobacter calcoaceticus, Neisseria gonorrhoeae (strains producing and non-producing beta-lactamases), Neisseria meningitides, Yersinia enterocolitica;
    anaerobic microorganisms - Gram-positive and Gram-negative cocci (including Peptococcus spp, Peptostreptococcus spp and Veillonella spp.);
    Gram-positive rods (including Clostridium spp., Eubacterium spp., And Lactobacillus spp);
    Gram-negative rods (including Fusobacterium spp., Many strains of Bacteroides fragilis and other representatives of the genus Bacteroides spp).
    Cefoperazone is also active in vitro for a wide range of other pathogens, however,
    the clinical significance of this is unknown: Salmonella and Shigella spp., Serratia liquefaciens, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica, Clostridium difficile, Fusobacterium spp .; Eubacterium spp. and strains of Haemophilus influenzae and Neisseria gonorrhoeae; producing beta-lactamases.
    Pharmacokinetics:
    The connection with plasma proteins is 82-93%. The time to reach the maximum concentration (TCmax) after intramuscular (IM) administration is 1-2 hours, after intravenous (IV) at the end of the infusion. The maximum concentration (Cmax) after the / m administration of 1 g and 2 g is 65-75 and 97 μg / ml, respectively; after a single intravenous injection of 1, 2, 3 and 4 g of Cmax-153, 252, 340 and 506 μg / ml, respectively. Stam in the urine after IM and in / in the introduction of 2 g-1 and more than 2.2 mg / ml, respectively.
    Achieves therapeutic concentrations in such tissues and body fluids as peritoneal, ascitic fluid and cerebrospinal fluid (CSF) (with meningitis), urine, bile, gallbladder walls, lungs, sputum, palatine tonsils and sinus mucosa, atria, kidneys, ureters, prostate, testicles, uterus, fallopian tubes, bones, cord blood and amniotic fluid. The volume of distribution is -0.14-2 l / kg. The half-life period (T1 / 2) is 1.6-2.4 hours, regardless of the mode of administration; 2,8-4,2 h- with hemodialysis; 2.2 h - in newborns and children from 2 months to 11 years. It is excreted with bile - 70-80%, kidneys - 20-30% unchanged.In patients with impaired liver function and bile duct obstruction T1 / 2 -3-7 hours, excretion by the kidneys is 90% or more. Even with severe liver damage, therapeutic concentrations are achieved in bile, and T1 / 2 is only 2-4 times longer. In patients with renal-hepatic insufficiency can accumulate.
    Indications:Infectious-inflammatory diseases caused by microorganisms sensitive to cefoperazone: bacterial infections of the upper and lower respiratory tract, urinary tract, peritonitis, cholecystitis, cholangitis and other intra-abdominal infections, sepsis, meningitis, skin and soft tissue infections, infections of bones and joints, infectious and inflammatory diseases of the pelvic organs (endometritis, gonorrhea and other infections of the genital tract).
    Prevention of infectious complications after abdominal, gynecological and orthopedic operations, as well as in cardiovascular surgery.
    Contraindications:Hypersensitivity to cefoperazone, as well as indications of allergic reactions to cephalosporins in the anamnesis, lactation period.
    Carefully:Renal and hepatic insufficiency, pregnancy, colitis in the anamnesis.
    Pregnancy and lactation:
    The use of the drug during pregnancy is possible only if the intended benefit for the mother exceeds the potential risk to the fetus.
    If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.
    Dosing and Administration:
    In / m and / in (slowly streaming or drip).
    The drug is injected deep in the / m into the large gluteus muscle or the anterior surface of the thigh.
    For IV injection, the maximum single dose is 2 g; duration of administration - at least 3-5 minutes. Duration iv in the drip introduction is 15-60 min.
    The dose for adults is 2-4 g / day, divided into 2 injections (every 12 hours). In severe infections, the dose can be increased to 8 g / day, divided into 2 injections (every 12 hours). Complications when used in a daily dose of 12-16 g, divided into 3 injections, was not detected. Treatment with the drug can begin before the results of a study of the sensitivity of microorganisms.
    With uncomplicated gonococcal urethritis - once in / m in a dose of 500 mg. Prevention of postoperative complications: 1 g or 2 g IV for 30-90 minutes before the operation, followed by repeated administration every 12 hours (in most cases within 24 hours).In operations with an increased risk of infection (for example, operations in the colorectal area), in open-heart surgery or joint replacement, prophylactic use can continue for 72 hours after the operation is completed.
    Dose adjustments may be required in cases of severe obstructed bile duct obstruction, severe liver disease, or concomitant liver and kidney dysfunction. In this case, the daily dose should not exceed 2 g, while there is no need to monitor serum concentrations.
    Because the cefoperazone is mainly excreted not through the kidneys, then dose adjustments for renal dysfunction when administered at recommended doses (2-4 g / day) are not required. Patients who have a glomerular filtration rate below 18 ml / min, or a serum creatinine concentration greater than 3.5 mg / dl, a daily dose should not exceed 4 g. With hemodialysis T1 / 2, cefoperazone from serum slightly decreases, so the drug should enter after the end of the dialysis session.
    It is recommended to monitor the concentration of cefoperazone in the blood serum (assuming that the daily dose is more than 2 g) with a combined disturbance of liver and kidney function and, if necessary, adjust the dose.
    The dose for children is 50-200 mg / kg / day, divided into equal parts, administered every 8-12 hours. The maximum dose is 12 g / day. With IV slow injection, the maximum single dose is 50 mg / kg; duration of administration - at least 3-5 minutes. Newborns (aged less than 8 days) - 50-200 mg / kg / day in equal parts every 12 hours.
    In the treatment of infections caused by Streptococcus pyogenes in adults and children, the duration of therapy should be at least 10 days. To prepare solutions for intramuscular injection, sterile water for injection, 0.9% solution of sodium chloride (to 1 g of cefoperazone add 3 ml of solvent).
    In cases where the solution is supposed to be in a concentration that exceeds 250 mg / ml, 0.5% lidocaine solution is recommended for solution preparation. Such a solution can be prepared using sterile water for injection and 2% (20 mg / ml) lidocaine solution, the final lidocaine concentration should be 0.5%. It is recommended to use a two-stage dissolution method: first, add the necessary amount of sterile water for injection, shake until the powder is completely dissolved, and then add the required amount of 2% lidocaine solution (see table):

    The content of cefoperazone in the vial, g

    The final concentration of the solution of cefoperazone in the vial, mg / ml

    Volume of sterile water, ml

    Volume of 2% lidocaine solution, ml

    The volume of the final solution taken for administration

    0,5

    250

    1,3

    0,45

    2,0

    0,5

    333

    0,9

    0,3

    1,5

    1

    250

    2,6

    0,9

    4,0

    1

    333

    1,8

    0,6

    3,0

    2

    250

    5,2

    1,8

    8,0

    2

    333

    3,7

    1,2

    6,0


    For the preparation of solutions for intravenous administration, the following solvents can be used:
    - dextrose 5 %;
    - 0.9% solution of sodium chloride;
    - sterile water for injections.
    For intravenous drip, the drug is dissolved at a rate of 5 ml of sterile
    water for injection per 1 g of cefoperazone, the resulting solution is added to the appropriate solution for intravenous administration to a concentration of 20-100 mg / ml. When used as a solvent for sterile water for injection, its volume should not exceed 20 ml.
    With intravenous slow jet injection, the drug is dissolved in a suitable solvent with a final concentration of 100 mg / ml and injected slowly for at least 3-5 minutes.
    Side effects:

    Allergic reactions: in t.ch. itching of the skin, maculopapular rash, urticaria, eosinophilia and drug fever; Stevens-Johnson syndrome; anaphylactoid reactions (including shock). The risk of developing allergic reactions is increased in patients with a tendency to allergic reactions (especially penicillin) in the anamnesis.

    Local Reactions: soreness (with the / m introduction), phlebitis in the place of / in the injection.

    From the side of the digestive system: diarrhea or loosening of the stool, nausea, vomiting, moderate transient increase in activity of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, pseudomembranous colitis.

    On the part of the organs of hematopoiesis: reversible neutropenia (with long-term treatment), false positive Coombs test, reduced hemoglobin or hematocrit, eosinophilia and hypoprothrombinemia, bleeding.

    Overdose:Symptoms: neurological disorders, including convulsions.
    Treatment: symptomatic sedation. Hemodialysis is effective.
    Interaction:
    Pharmaceutically incompatible with aminoglycosides (if necessary, combined therapy with cefoperazone and aminoglycoside is prescribed as a sequential fractional intravenous drug administration (LS), using 2 separate IV catheters.
    If you take alcohol during treatment or for 5 days after using cefoperazone, it is possible to develop a disulfiram-like reaction, manifested by "hot flashes", increased sweating, headache and tachycardia.Patients should be warned about the danger of taking alcohol during the application of cefoperazone. For patients who are on oral or parenteral artificial feeding, solutions containing alcohol should be excluded. Indirect anticoagulants, heparin sodium, fibrinolytic drugs increase the risk of hypoprothrombinemia, bleeding.
    Aminoglycosides and looped diuretics increase the risk of developing nephrotoxicity, especially in individuals with renal insufficiency.
    LS, reducing tubular secretion, increase the concentration of the drug in the blood and slow its elimination.
    Special instructions:
    The drug can be used in combination therapy in combination with other antibiotics.
    Before treatment it is necessary to collect a detailed allergological anamnesis in order to identify the patient's hypersensitivity to cephalosporins, penicillins and other drugs. Patients with hypersensitivity to penicillin should be administered with caution because of possible cross-sensitivity. If an allergic reaction occurs during treatment, cefoperazone should be discontinued and appropriate treatment initiated. Cefoperazone is largely excreted with bile. In patients with liver disease or obstructed bile ducts, T1 / 2 cefoperazone from the blood plasma is usually lengthened, and the excretion of the drug by the kidneys is increased. Nevertheless, even with severe violations of liver function in bile, "therapeutic" concentrations of cefoperazone are achieved, and T1 / 2 is only 2-4 times longer. In some patients, treatment with cefoperazone may lead to vitamin K deficiency in the body, which is due to the suppression of the intestinal flora that synthesizes this vitamin.
    The greatest risk is susceptible, patients with malabsorption syndrome (for example, in cystic fibrosis), as well as patients who adhere to a defective diet or who are for a long time on parenteral nutrition. In such patients during the treatment should monitor prothrombin time, and if necessary, prescribe vitamin K.
    With prolonged therapy, it is recommended to periodically monitor the kidneys, liver and hematopoiesis. This is especially important for newborns, especially premature and small children.
    Clostrifium difficile associated diarrhea is observed against the background of almost all antibacterial drugs, including cefoperazone, and is manifested from mild forms of diarrhea to severe colitis with a fatal outcome. Treatment with antibacterial drugs leads to disruption of normal colon microflora, resulting in increased growth of Clostrifium difficile, producing toxins A and B, which lead to the development of Clostrifium difficile associated diarrhea. Hypertoxin-producing strains of Clostrifium difficile lead to an increase in morbidity and mortality, since they can be resistant to antibiotic therapy. All cases of diarrhea in patients with antibiotic therapy should be considered as suspicious for the development of Clostrifium difficile associated diarrhea.
    During treatment, a false positive reaction to glucose in the urine is possible, while conducting a study using solutions of Benedict or Felling.
    If it is necessary to use the drug in newborns, incl. premature, the expected positive effects of therapy and the possible risk associated with treatment should be considered.
    In newborns with nuclear jaundice cefoperazone Do not displace bilirubin from the connection with plasma proteins.
    The stability of the prepared solutions depends on their concentration and the nature of the solvent. Shelf life should not exceed 24 hours at room temperature, 5 days - when stored in the refrigerator, at a temperature of 2 to 8 ° C for weeks, at temperatures from minus 10 to minus 20 ° C. Solutions should be stored in glass or plastic syringes, glass or plastic bottles intended for storage of solutions for parenteral administration:
    Thawing of the frozen preparation should occur at room temperature. The solution can not be re-frozen. After thawing, the unused solution of the drug must be disposed of.

    Effect on the ability to drive transp. cf. and fur:The use of the drug does not affect the management of vehicles and the maintenance of machines and mechanisms that require special attention and quick reactions.
    Form release / dosage:
    Powder for solution for intravenous and intramuscular injection 0.5 g, 1 g, 2 g.

    Packaging:
    0.5 g, 1 g, 2 g of cefoperazone in glass vials of 10 ml, 20 ml, hermetically sealed with rubber stoppers, crimped aluminum caps or aluminum caps combined with plastic lids.
    1, 5, 10 bottles with instructions for use in a pack of cardboard.
    50 bottles with an equal number of instructions for use in a cardboard box for delivery to hospitals.
    Solvent: - "Water for injection" in glass ampoules of 5 ml; or
    "Sodium chloride solvent for the preparation of medicinal forms for injection 0.9%" in glass ampoules of 5 ml;
    1 bottle with the preparation, 1 or 2 ampoules with a solvent in a contoured cell pack from a polyvinyl chloride film.
    1 contour pack with instructions for use and ampoule ampoule in a pack of cardboard.
    1 vial, 1 or 2 with a solvent ampoule, with instructions for use and a lancet ampulnam bundle or box made of cardboard.
    5 bottles of the drug in a contour cell pack from a polyvinyl chloride film.
    1, 2 contour mesh packages with vials of the preparation and instructions for use in a pack of cardboard.
    1 contour mesh package with vials of the preparation, 1 or 2 contour mesh packages with solvent ampoules (5 ampoules each), instructions for use and ampoule ampoule in a pack of cardboard.
    When using ampoules with a kink ring or with a notch and a dot the ampoule scaper is not inserted.
    Storage conditions:
    In a dry, the dark place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:
    3 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001874
    Date of registration:30.08.2011
    The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp27.10.2015
    Illustrated instructions
      Instructions
      Up